Valsoft reinforces global car rental management leadership with acquisition of Thermeon Worldwide Limited
MONTREAL, Nov. 21, 2018 (GLOBE NEWSWIRE) -- Valsoft Corporation Inc. (“Valsoft”), a Montreal-based company that specializes in the acquisition and development of vertical market software businesses, is pleased to announce the acquisition of Thermeon Worldwide Ltd (“Thermeon”), a global industry-leading provider of car rental software headquartered in the UK with regional offices in the United States and Australia. Under the agreement, Valsoft will acquire Thermeon’s assets, including its brand name, CARS+.
CARS+ provides the tools to manage the rental process from quotation and accounting to signature capture and credit card processing. CARS+ is used worldwide by most leading multinational brands and trusted local companies, at service counters, in fleet management, accounting, corporate management, and, most importantly, in Web and mobile customer interfaces.
Thermeon, which was launched in 1967 under the guidance of Rollo Pickford, celebrated its 50th birthday in 2017. In the early 1990s, Terry Pearson and Robin Redmile-Gordon became distributors of CARS+ in the APAC and EMEA regions respectively, working closely with Scott Sampson and the Thermeon team in the U.S. to develop and expand the functionality and reach of CARS+. In 2016, the three regions united to form a single global company.
“Thermeon has always been built on outstanding customer service. Our customers and our global team are our most treasured assets, as well as our most important responsibilities,” stated Robin Redmile-Gordon, Thermeon’s chairman. “When considering new ownership, we wanted to join someone who would put those two groups front and centre. We believe Valsoft is exactly the right company to uphold our precious reputation and carry on that proud tradition.”
The entire Thermeon management team will continue to lead the business under Valsoft’s ownership, maintaining its high customer service standards and comprehensive suite of products. In addition, Valsoft is committed to investing substantially in the car rental industry to drive innovation and digital transformation.
“We are thrilled to welcome Thermeon’s dedicated employees and loyal customers into the Valsoft family. Joining forces with Thermeon has enabled us to achieve an incredible milestone: to expand and reinforce our position as global market leader in the car rental software industry,” said Michael Assi, CEO of the Travel and Leisure division at Valsoft. “Thermeon and Valsoft share the same values: a passion for innovation, world-class customer experience and a desire to grow.”
For more than 40 years, Thermeon has been a global source of knowledge and best practices in the car rental industry. Our powerful and innovative car rental software solutions support operators worldwide, delivering high-quality vehicle hire systems that help both global and independent businesses to maximise revenue and drive sales.
CARS+ is at the core of Thermeon, providing the fastest complete car rental system on the market. Our customers and partners span 40 countries across six continents and provide a trusted source of skills in the car rental market. With offices in Europe, The Americas and Australia, the Thermeon global team specializes in building the right systems for any fleet size and budget.
About Valsoft Corporation:
Valsoft Corporation acquires and develops vertical market software companies, enabling each business to deliver the best mission-critical solutions for customers in their respective industry or niche.
A key tenet of Valsoft’s philosophy is to invest in well-established businesses and foster an entrepreneurial environment that shapes a company into a leader in its respective industry. Unlike private equity and VC firms, Valsoft does not have a predefined investment horizon and looks to buy, hold, and create value through long-term partnerships with existing management and customers.
Valsoft Corporation was represented internally by David Felicissimo, General Counsel & Aude Florin, Legal Counsel and external counsel Caroline Harwood of Rooney Nimmo. Thermeon Worldwide Limited was represented by Bryan Bletso and Charlie Milsom of Irwin Mitchell LLP.
|Sources:||https://www.thermeon.com/ and https://www.valsoftcorp.com/|
|Media relations:||Leeja Murphy, Agence Pink
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg saker fra GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra GlobeNewswire
Biome Grow receives new consumer sales amendment from Health Canada for its Nova Scotia brand, Highland Grow17.12.2018 14:00 | Pressemelding
Sales amendment granted for Highland Grow—Amendment to License Significantly Increases Product Availability for Medical and Adult Consumer-Use Markets TORONTO, Dec. 17, 2018 (GLOBE NEWSWIRE) -- Biome Grow Inc. (“Biome” or the “Company”) (CSE: BIO) (Frankfurt: 6OTA) (OTC: ORTFF) is pleased to announce its Nova Scotia-based subsidiary, Highland Grow Inc. (“Highland Grow”), has received its sales authorization via an amendment to its existing license from Health Canada under the Cannabis Act. This authorization will allow Highland Grow to sell cannabis products to end consumers through appropriate medical and recreational cannabis channels, dramatically increasing product availability. The sales authorization will position Biome Grow to serve the rapidly growing domestic and international cannabis markets. "Biome Grow has been steadfast in its focus on a regional business strategy and building provincial brands that can serve the unique requirements of its local cannabis consumers. This n
Alkermes and Biogen Announce Submission of a New Drug Application to U.S. Food and Drug Administration for Diroximel Fumarate in Multiple Sclerosis17.12.2018 13:30 | Pressemelding
DUBLIN, Ireland and CAMBRIDGE, Mass., Dec. 17, 2018 (GLOBE NEWSWIRE) -- Alkermes plc (Nasdaq: ALKS) and Biogen Inc. (Nasdaq: BIIB) today announced that Alkermes has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for diroximel fumarate (BIIB098), a novel oral fumarate in development for the treatment of relapsing forms of multiple sclerosis (MS). Alkermes is seeking approval of diroximel fumarate under the 505(b)(2) regulatory pathway, and the NDA submission includes data from EVOLVE-1, a Phase 3 pivotal trial that evaluated long-term safety in relapsing-remitting MS (RRMS) with approximately 700 patients dosed with diroximel fumarate. If approved, Biogen intends to market diroximel fumarate under the brand name VUMERITY™. This name has been conditionally accepted by the FDA and will be confirmed upon approval. “Diroximel fumarate was designed to provide patients with relapsing forms of multiple sclerosis a novel oral fumarate with a differentiated
SoftServe Documentary Receives “The Best Corporate Media of Ukraine 2018” Award17.12.2018 13:00 | Pressemelding
25th anniversary documentary takes prize in “The Best Corporate Movie” category AUSTIN, Texas, Dec. 17, 2018 (GLOBE NEWSWIRE) -- SoftServe, a leading digital authority and consulting company, announces the Ukrainian Association of Corporate Media, a public organization uniting professionals in the field of marketing, PR, journalism, and advertising, recognized SoftServe in its annual competition – “The Best Corporate Media of Ukraine 2018.” SoftServe’s 25th anniversary documentary took second place in the “The Best Corporate Movie Category.” The documentary honors the company’s 25th anniversary with an inside look at how SoftServe evolved over the past quarter century to become a leading digital authority. In the documentary, SoftServe’s founders and leadership share their inspiring stories and highlight the company’s achievements over the years. “It is a great honor to receive this recognition from the Ukrainian Association of Corporate Media for our 25th anniversary documentary,” sai
Bombardier to supply a further 20 FLEXITY trams to Karlsruhe17.12.2018 10:00 | Pressemelding
Albtal-Verkehrs-Gesellschaft expands its fleet to 62 trams The dual-system vehicles operate on both the tram network and regional railway network BERLIN, Dec. 17, 2018 (GLOBE NEWSWIRE) -- Global mobility solution provider Bombardier Transportation received a call-off order from Albtal-Verkehrs-Gesellschaft mbH (AVG), the transport company of the Alb valley region in southwest Germany, for the delivery of 20 further dual-system BOMBARDIER FLEXITY trams. This third order is based on a framework agreement for a total of 75 vehicles from 2009. The order is valued at approximately 87 million euro ($98 million US). The vehicles will be delivered between May 2020 and March 2021. "Striving to provide attractive local transport services, we have decided to order 20 additional dual-system vehicles from Bombardier Transportation. This will allow us to purposefully enlarge our vehicle fleet offering high-quality standards to our passengers," said Dr. Alexander Pischon, CEO of Albtal-Verkehrs-Gesel
DalCor Announces Completion of Patient Enrollment in dal-GenE, the First Phase 3 Precision Medicine Cardiovascular Outcomes Trial in Coronary Heart Disease17.12.2018 09:00 | Pressemelding
LONDON and MONTREAL, Dec. 17, 2018 (GLOBE NEWSWIRE) -- DalCor today announced the completion of patient enrollment in the dal-GenE study, the first Phase 3 precision medicine cardiovascular outcomes trial in coronary heart disease. The dal-GenE study is evaluating the efficacy of the CETP inhibitor dalcetrapib to reduce clinical cardiovascular events in patients with the AA ADCY9 genotype who have had a recent acute coronary syndrome (ACS). The study has enrolled over 6,000 patients and is being conducted in 680 sites in 32 countries. “The accelerated enrollment of patients in the dal-GenE study reflects the scientific enthusiasm and commitment among the medical community to bring the right medicine to the right patient,” said Dr. Jean-Claude Tardif from the Montreal Heart Institute. “ADCY9 genetic testing to identify the appropriate patients for treatment with dalcetrapib has the potential to provide a genetically targeted therapy to improve clinical outcomes. This approach could pave
Compuware Announces Day One Support for IBM CICS Transaction Server for z/OS V5.514.12.2018 18:02 | Pressemelding